02/06/2020
Matters of the Prostrate
Meet my good Friend Ian Sauter! He is genuinely made from the salt of the earth and a keen outdoors man with a zest for life . Just like many of my other friends that are starting to comb out a few grey hairs out and that have been poked and prodded after discovering high PSA level, which believe me will scare the holy bejesus out of any man, have started using Malberry full spectrum CBD oil with great results Ian’s PSA came down from 49.6 to 2.9 . For those who don’t know what PSA stands for, it is a blood test used primarily to screen for prostate cancer. The test measures the amount of Prostate-Specific Antigen (PSA) in your blood. PSA is a protein produced by both cancerous and noncancerous tissue in the prostate, a small gland that sits below the bladder in men. A prostate examination requires a visit to the doctor who is going to insert a well lubricated index finger on a gloved hand… not nice.
• 0 to 2.5 ng/mL is considered safe
• 2.6 to 4 ng/mL is safe in most men but talk with your doctor about other risk factors
• 4.0 to 10.0 ng/mL is suspicious and might suggest the possibility of prostate cancer. It is associated with a 25% chance of having prostate cancer.
• 10.0 ng/mL and above is dangerous and should be discussed with your doctor immediately. It is associated with a 50% chance of having prostate cancer
The dreaded PSA test and a prostate examination have to be one of the most unwelcome endeavors a man must face in his lifetime. Around the world excluding non-melanoma skin cancer, Prostate cancer is the most common cancer in men and the second cause for cancer-related death. Even though most cases of prostate cancer are a localized disease at the time of diagnosis, it’s estimated approximately 7% of men still end up with metastatic disease. The most common site of spread of prostate cancer is bone. This malignant tumor cell growth preferentially occurs in bones of the axial skeleton. Lesions are more symptomatic, causing pain, debility, functional impairment are a direct impact on a man’s quality of life. However all is not lost. Recent research demonstrates that there is some evidence that shows that prostate tissue possesses cannabinoid receptors and their stimulation results in anti-androgenic effects. Anti-androgen is drug that blocks the action of androgens. Androgens , indicates the male s*x hormones. Full spectrum CBD oils thus make sense not only from an anti-androgenic perspective but also for men with bone metastatic prostate cancer and therefore a better pain management can be attained with less opioids used to control pain. Full Spectrum Cannabis oils thus offer a unique and a different method of managing pain.
Canabinoids possess a quality or feature that has an impact in both cancer pain and prostate cancer pathophysiology. Pathophysiology now there is a huge word, before you reach for the dictionary it means ‘’the disordered physiological processes associated with disease or injury’’ in other words the fear and stress factor that comes with cancer. Cannabinoid compounds harbor analgesic and anti inflammatory properties that aid bone cancer pains that will help reduce opioid dependency as well as exhibiting anti-androgenic effects in prostate cancer cells. So Understanding the use of FSCBD oils target values : At the peripheral level CB 2 receptors are localized in the adrenal gland, adipose tissue, heart, lung, liver prostate, o***y, uterus, te**is, bone marrow, thymus, tonsils, and presynaptic nerve terminals. Notably for cancer sufferer and pain management purposes CB1 receptors are found at central and peripheral levels of the control pain pathways. Thus the distribution of cannabinoid receptors amazingly provides an anatomical explanation for the analgesic effects of full spectrum CBD oil.
REFERENCES
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin.
2. Dr Edward McFadden, Malcolm Berry. Concepts in Cannabis Genetics and Cancer 1993 Malberry
3.Devane WA, Dysarz FA, 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34:605–13. [PubMed] [Google Scholar]
4. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: What we know and what we need to know. Ann Intern Med. 1993;119:914–23. [PubMed]